For most businesses, a major competitor shutting their doors would be welcome. But for pharmacists, taking on new clients can ...

MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

The American Society for Clinical Oncology’s Annual Meeting for 2025 is, if nothing else, absolutely overwhelming and ...

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...

The president’s proposed 25 percent tariffs on pharmaceutical imports will be catastrophic. There are other options to bring ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer ...

Tobacco-funded research is still appearing in highly-cited medical journals - despite attempts by some to cut ties altogether ...

As a sales rep for drug manufacturers Questcor, Lisa Pratta always suspected the company’s business practices weren’t just ...

Despite the long holiday weekend, news in biopharma never slows down. | This week on "The Top Line," we break down ...

Notably, the U.S.’ two primary biopharma trade groups—the Pharmaceutical Research and Manufacturers of America (PhRMA) and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.